Xinghai Forum: I CAME, I SAW, I-SPY—Exploring the Highlights of the I-SPY 2.2 Study and Its Clinical Practice Value

Xinghai Forum: I CAME, I SAW, I-SPY—Exploring the Highlights of the I-SPY 2.2 Study and Its Clinical Practice Value

From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was grandly held, bringing together cutting-edge developments from home and abroad. At the previous ASCO conference, the results of the I-SPY 2.2 study were released, providing new insights into optimizing neoadjuvant treatment plans for breast cancer, exploring the application of immune checkpoint inhibitors combined with antibody-drug conjugates (ADCs), and investigating step-up and step-down treatment strategies. At the Xinghai Forum, Oncology Frontier invited Professor Shu Wang from Peking University People's Hospital, Professor Zhigang Yu from Qilu Hospital of Shandong University, Professor Haibo Wang from The Affiliated Hospital of Qingdao University, and Professor Guangyu Liu from Fudan University Shanghai Cancer Center to discuss the highlights of the I-SPY 2.2 study and its reference value for clinical practice.
EHA China’s Voice : Professor Jia Wei’s Team on UBE2Q1’s Impact on Antigen Presentation in AML and Clinical Prognosis and Molecular Characteristics

EHA China’s Voice : Professor Jia Wei’s Team on UBE2Q1’s Impact on Antigen Presentation in AML and Clinical Prognosis and Molecular Characteristics

The 29th Annual Congress of the European Hematology Association (EHA) was held grandly in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Jia Wei's team from Tongji Hospital, Huazhong University of Science and Technology had multiple studies selected for poster or e-poster presentations. This issue focuses on two studies in the field of myeloid tumors. One study (P487), conducted in collaboration with Associate Professor Yu Xiaoxuan from Nanjing University of Chinese Medicine, explores the relationship between UBE2Q1 and AML prognosis and its mechanism of affecting antigen presentation in AML. The other study (P1885) investigates the clinical prognosis and molecular characteristics of MDS patients with ASXL1 mutations.
15th International T-Cell Lymphoma Forum丨Professor Wenyu Shi and Dr. Yi Miao: Application of EASIX in Predicting Survival of T/NK-LA HLH Patients

15th International T-Cell Lymphoma Forum丨Professor Wenyu Shi and Dr. Yi Miao: Application of EASIX in Predicting Survival of T/NK-LA HLH Patients

A research study led by Professor Wenyu Shi from the Affiliated Hospital of Nantong University and Dr. Yi Miao from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial Hospital), under the Jiangsu Lymphoma Collaboration Group and the Jiangsu HLH Working Group, was selected for an oral presentation. This study is the first to show that the Endothelial Activation and Stress Index (EASIX) is a reliable predictor of outcomes in patients with T/NK cell lymphoma-associated hemophagocytic lymphohistiocytosis (T/NK-LA HLH).The 15th International T-Cell Lymphoma Forum successfully took place from June 6 to 8, 2024, in San Diego, USA. This forum brought together top clinicians, researchers, and distinguished representatives from the medical field worldwide, aiming to advance the research and innovation in T-cell lymphoma, ultimately improving patient survival and well-being.  "Oncology Frontier - Hematology Frontier" invited Professor Shi and Dr. Miao for an interview to share and interpret the study's content and significance.
Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA meeting, a study (S119) by Professor Xian Zhang from Beijing Lu Daopei Hospital was selected for oral presentation. The study explored immune reconstitution in R/R T-ALL/LBL patients following CD7 CAR-T therapy. “Oncology Frontier - Hematology Frontier” interviewed Professor Xian Zhang to introduce and interpret the study's content and topics related to the treatment of R/R T-ALL/LBL.
EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.
ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient's immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown promising efficacy in clinical trials. In the phase II KEYNOTE-942 study, mRNA-4157 combined with pembrolizumab extended relapse-free survival (RFS) for high-risk melanoma patients compared to pembrolizumab alone. At this year's ASCO meeting, the study presented updated 3-year follow-up data. Oncology Frontier has compiled and summarized the findings for our readers.
ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier has compiled and summarized the relevant content for our readers.
JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients

JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients

Recently, Professor Naga P. Chalasani and his research team from Indiana University published a significant study online in the prestigious hepatology journal JOH. The study, titled "Increases and Decreases in Liver Stiffness Measurements are Independently Associated with the Risk of Liver-Related Events in NAFLD Patients," was initiated by Professor Naga P. Chalasani in collaboration with key researchers in the NAFLD field across the United States, including Professor Arun J. Sanyal from Virginia Commonwealth University. The study aims to provide new insights into disease management and risk assessment for NAFLD patients.
ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer

ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer

The treatment of advanced hepatocellular carcinoma (HCC) has entered the era of targeted and immunotherapy, with combined regimens becoming the first-line standard. More combination therapies are still under exploration. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the CheckMate 9DW study announced positive results for the dual immunotherapy of anti-PD-L1 and anti-CTLA-4, positioning this "double star" regimen as a potential first-line treatment. Additionally, the conference revealed results from the first Phase II clinical trial of an immune checkpoint inhibitor (ICI) combined with a tyrosine kinase inhibitor (TKI) as a second-line treatment following failure of first-line immunotherapy. Chinese researchers also reported on a Phase I clinical trial of a specific autologous armored-CAR-T cell therapy.
ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC

ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC

The CHAARTED study demonstrated that early use of chemotherapy combined with androgen deprivation therapy (ADT+docetaxel) significantly improves survival for most patients with metastatic hormone-sensitive prostate cancer (HSPC). However, most patients eventually develop castration-resistant prostate cancer (CRPC) and require additional systemic treatment. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Christos Kyriakopoulos from the University of Wisconsin Carbone Cancer Center shared the results of the CHAARTED2 clinical study on cabazitaxel combined with abiraterone for metastatic prostate cancer. "Oncology Frontier" interviewed Professor Christos Kyriakopoulos to discuss treatment options for CRPC.